259 related articles for article (PubMed ID: 24056649)
1. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
2. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
3. An approach to malignant mammary phyllodes tumors detection.
Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
[TBL] [Abstract][Full Text] [Related]
4. Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.
Shapochka DO; Zaletok SP; Gnidyuk MI
Exp Oncol; 2012 Dec; 34(4):358-63. PubMed ID: 23302996
[TBL] [Abstract][Full Text] [Related]
5. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
6. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
7. Increased p53 protein expression in malignant mammary phyllodes tumors.
Tse GM; Putti TC; Kung FY; Scolyer RA; Law BK; Lau TS; Lee CS
Mod Pathol; 2002 Jul; 15(7):734-40. PubMed ID: 12118111
[TBL] [Abstract][Full Text] [Related]
8. Utility of Ki-67, CD10, CD34, p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast.
Vilela MH; de Almeida FM; de Paula GM; Ribeiro NB; Cirqueira MB; Silva AL; Moreira MA
Int J Surg Pathol; 2014 Sep; 22(6):485-91. PubMed ID: 24492332
[TBL] [Abstract][Full Text] [Related]
9. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
10. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
11. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast.
Chan YJ; Chen BF; Chang CL; Yang TL; Fan CC
J Chin Med Assoc; 2004 Jan; 67(1):3-8. PubMed ID: 15077883
[TBL] [Abstract][Full Text] [Related]
12. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
[TBL] [Abstract][Full Text] [Related]
14. Phyllodes tumors and fibroadenoma common beginning and different ending.
Oprić S; Oprić D; Gugić D; Granić M
Coll Antropol; 2012 Mar; 36(1):235-41. PubMed ID: 22816226
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
16. CD34, CD117, and actin expression in phyllodes tumor of the breast.
Chen CM; Chen CJ; Chang CL; Shyu JS; Hsieh HF; Harn HJ
J Surg Res; 2000 Dec; 94(2):84-91. PubMed ID: 11104647
[TBL] [Abstract][Full Text] [Related]
17. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features.
Suo Z; Nesland JM
Ultrastruct Pathol; 2000; 24(6):371-81. PubMed ID: 11206334
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptors expression in phyllodes tumors of the breast.
Kim YH; Kim GE; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Anal Quant Cytol Histol; 2012 Feb; 34(1):41-8. PubMed ID: 22590818
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
